Show simple item record

dc.contributor.authorFiorillo, Marco
dc.contributor.authorSotgia, F
dc.contributor.authorSisci, D
dc.contributor.authorCappello, A
dc.contributor.authorLisanti, M
dc.date.accessioned2017-04-19T16:49:33Z
dc.date.available2017-04-19T16:49:33Z
dc.date.issued2017-03-20
dc.identifier.citationMitochondrial “power” drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer. 2017, Oncotargeten
dc.identifier.issn1949-2553
dc.identifier.doi10.18632/oncotarget.15852
dc.identifier.urihttp://hdl.handle.net/10541/620254
dc.relation.urlhttp://www.oncotarget.com/abstract/15852en
dc.rightsArchived with thanks to Oncotargeten
dc.titleMitochondrial “power” drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer.
dc.typeArticleen
dc.contributor.departmentThe Paterson Institute, University of Manchester, Withington, M20 4BX, United Kingdomen
dc.identifier.journalOncotargeten
refterms.dateFOA2018-12-17T14:54:20Z


Files in this item

Thumbnail
Name:
Onco15852-233744-7-PB.pdf
Size:
6.610Mb
Format:
PDF
Description:
Full text, Open Access Article

This item appears in the following Collection(s)

Show simple item record